If GLP-1 therapy is initiated , a structured monitoring plan should include: Regular assessment of weight, BMI and nutritional status Monitoring of hydration and renal function, particularly if experiencing significant gastrointestinal symptoms For diabetes patients, appropriate retinopathy surveillance if glycaemic control improves rapidly (especially with semaglutide) [5] [11] Regular review of Crohn's disease activity using clinical and biochemical markers Remember that you are an active participant in your healthcare decisions, and your concerns and experiences should guide the treatment plan
Manufactured in an FDA inspected facility
The prescribing information notes that GLP-1 agonists have not been studied in patients with a history of pancreatitis, so whether to use them, and how closely to monitor, is an individualized decision rather than a blanket yes or no
This matters because muscle is metabolically active tissue that supports a healthy metabolism long-term
Ultimately, the journey to better health is yours
Skipping weekly doses or extending the time between injections reduces effectiveness and may allow appetite to return to baseline
